KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$65.0 million.

  • Arbutus Biopharma's Free Cash Flow rose 71.95% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.4 million, marking a year-over-year increase of 36.94%. This contributed to the annual value of -$65.0 million for FY2024, which is 25.20% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Free Cash Flow of -$65.0 million as of FY2024, which was up 25.20% from -$86.9 million recorded in FY2023.
  • Over the past 5 years, Arbutus Biopharma's Free Cash Flow peaked at -$35.9 million during FY2022, and registered a low of -$86.9 million during FY2023.
  • Its 3-year average for Free Cash Flow is -$62.6 million, with a median of -$65.0 million in 2024.
  • As far as peak fluctuations go, Arbutus Biopharma's Free Cash Flow surged by 47.52% in 2022, and later crashed by 142.40% in 2023.
  • Over the past 5 years, Arbutus Biopharma's Free Cash Flow (Yearly) stood at -$51.7 million in 2020, then tumbled by 32.26% to -$68.3 million in 2021, then surged by 47.52% to -$35.9 million in 2022, then slumped by 142.40% to -$86.9 million in 2023, then grew by 25.20% to -$65.0 million in 2024.